<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> SJMN91-06075202 </DOCNO><ACCESS> 06075202 </ACCESS><DESCRIPT>  ELDERLY; DISEASE; DRUG; TRIAL; RESULT  </DESCRIPT><LEADPARA>  Clinical trial results on the first proposed Alzheimer's disease drug weremixed, with some measures showing improvement in patients and others producingno significant statistical findings.;    At a hearing before a Food and DrugAdministration Advisory Committee, Warner-Lambert Co. said it believedclinical trials of the drug Tacrine at 16 university hospitals showed clearimprovement in patients.  </LEADPARA><SECTION>  Front  </SECTION><HEADLINE>  ALZHEIMER'S FIRST DRUG GETS MIXED TRIAL RESULTS  </HEADLINE><TEXT>     But Ronald M. Cresswell, Warner-Lambert vice president, acknowledged theresults were unclear for one of two scales used to measure the drug.;   Researchers assessed the effects of the drug by a test called the Alzheimer'sDisease Assessment Scale and by an objective evaluation by doctors called theClinical Global Indication of Change.;    Works well in recall tests; Cresswell said that under the ADAS test, which examined patients' ability torecall words, there was an &quot;overwhelmingly statistically significant&quot; findingin favor of the drug.;    However, the CGIC test produced no statisticallysignificant results, he said.;    &quot;The study is going to be criticized, weknow that,&quot; said Cresswell.;    However, the drug company official said thatin the objective test, in which memory was examined with such factors as wordrecognition, there were signs of improvement.;    &quot;It is a drug we will showimproves the quality of life for patients,&quot; he said.;    Significance unclear; He claimed that 41 percent of the patients tested got better scores on theobjective test while saying the CGIC scores &quot;did not reach a statisticallysignificant benefit.&quot;;    He asked the FDA panel to evaluate the relativemerits of the test and noted &quot;the public has waited for years for a response&quot;on testing of this drug.;    A panel of FDA experts heard reports on theclinical studies and was to vote on a recommendation later today. Final actionby the FDA could take months.;    Tacrine, or THA, is the first drug to beproposed for FDA approval in the treatment of Alzheimer's disease. It has lefta trail of controversy through more than five years of research.;   Warner-Lambert proposes to market the drug under the name Cognex.;    Sourcesfamiliar with the studies say THA has shown it can improve the thinkingprocesses in some Alzheimer's patients, but, at the same time, the drug canpose a serious risk of liver damage if misused.;    &quot;It's going to be a closecall,&quot; said a researcher who spoke on condition of anonymity. &quot;It's really aquestion of trade-offs.&quot;  </TEXT><BYLINE>  Associated Press  </BYLINE><COUNTRY>  USA  </COUNTRY><CITY>  Rockville, Md.  </CITY><EDITION>  Stock Final  </EDITION><CODE>  SJ  </CODE><NAME>  San Jose Mercury News  </NAME><PUBDATE>   910315  </PUBDATE> <DAY>  Friday  </DAY><MONTH>  March  </MONTH><PG.COL>  16A  </PG.COL><PUBYEAR>  1991  </PUBYEAR><REGION>  WEST  </REGION><STATE>  CA  </STATE><WORD.CT>  398  </WORD.CT><DATELINE>  Friday March 15, 199100075202,SJ1  </DATELINE><COPYRGHT>  Copyright 1991, San Jose Mercury News  </COPYRGHT><LIMLEN>  1  </LIMLEN><LANGUAGE>  ENG  </LANGUAGE></DOC>